首页|期刊导航|海南医学院学报|长期低剂量鹧鸪茶与中风的关系:一项基于海南的横断面研究

长期低剂量鹧鸪茶与中风的关系:一项基于海南的横断面研究OA北大核心CSTPCD

Association between long-term low-dose partridge tea and stroke:A cross-sectional study based on Hainan

中文摘要英文摘要

目的:探究长期低剂量饮用鹧鸪茶与降低中风发生率之间的关系.方法:采用横断面调查的方法,于2023年4月~2024年5月期间在海南省文昌市和万宁市对60岁及以上老年人进行走访,根据研究对象鹧鸪茶的饮茶历史、频次和单次喝茶时长,按等频率划分法分为常饮茶组、低饮茶组和不饮茶组.结果:共走访老年人849例,三组近3年内发生中风97人,组间差异具有统计学意义(P=0.001).在中风最严重时、中风三个月和一年后,经Kruskal-Wallis检验,三组间的NIHSS评分和mRS评分比较结果显示差异均具有统计学意义(P<0.05),这种差异在不饮茶组和常饮茶组之间更为显著(P<0.05).多因素Logistic回归分析结果显示:长期低剂量饮用鹧鸪茶是中风的保护因素(OR=0.465,95%CI=0.256~0.822,P<0.05),而冠心病(OR=1.814,95%CI=1.039~3.114)、高血压(OR=3.074,95%CI=1.893~5.074)、糖尿病(OR=5.898,95%CI=3.690~9.523)是发生中风的危险因素.有序Logistic回归分析结果显示:中风后 3个月(OR=0.201,95%CI=0.084~0.479)、中风后 1 年(OR=0.013,95%CI=0.002~0.105)、常饮茶(OR=0.071,95%CI=0.014~0.357)是中风患者神经功能恢复的保护因素;冠心病(OR=2.758,95%CI=1.221~6.233)、高血压(OR=3.204,95%CI=1.052~9.753)、糖尿病(OR=2.950,95%CI=1.259~6.914)是中风患者神经功能恢复的危险因素.中风后3个月(OR=0.121,95%CI=0.054~0.260)、中风后1年(OR=0.012,95%CI=0.004~0.028)、低饮茶(OR=0.146,95%CI=0.067~0.308)、常饮茶(OR=0.013,95%CI=0.005~0.031)是中风患者生活质量恢复的保护因素;年龄(OR=1.066,95%CI=1.027~1.108)、冠心病(OR=2.109,95%CI=1.115~4.054)、高血压(OR=2.053,95%CI=1.126~3.773)是中风患者生活质量恢复的危险因素.结论:长期低剂量饮用鹧鸪茶可以降低中风发生率,且可以改善中风患者的临床症状.

Objective:To explore the relationship between long-term low-dose consumption of partridge tea and reduced inci-dence of stroke.Methods:From April 2023-May 2024,a cross-sectional survey was conducted in Wenchang and Wanning,cit-ies of Hainan Province.Base on the drinking history,frequency,and single drinking time of partridge tea,the subjects were divid-ed into three groups using the equal frequency division method:a regular tea-drinking group,a low tea-drinking group,and a no tea-drinking group.Results:A total of 849 elderly people were interviewed.The number of stroke cases in the past 3 years was 97 among the three groups,and the difference was statistically significant(P=0.001).The differences of NIHSS and mRS scores among the three groups were statistically significant by the Kruskal-Wallis test at the most severe stroke,three months,and one year after stroke(P<0.05).The difference between no tea-drinking group and regular tea-drinking group was more significant(P<0.05).Multivariate logistic regression analysis showed that long-term low-dose partridge tea drinking was a protective factor for stroke(OR=0.465,95%CI=0.256~0.822,P<0.05).Coronary heart disease(OR=1.814,95%CI=1.039~3.114),hyper-tension(OR=3.074,95%CI=1.893~5.074),diabetes(OR=5.898,95%CI=3.690~9.523)were risk factors for strokes.Or-dinal logistic regression analysis showed that:3-months after stroke(OR=0.201,95%CI=0.084~0.479),1-year after stroke(OR=0.013,95%CI=0.002~0.105),and long-term low-dose partridge tea drinking(OR=0.071,95%CI=0.014~0.357)were protective factors for neural function recovery in patients with stroke;coronary heart disease(OR=2.758,95%CI=1.221~6.233),hypertension(OR=3.204,95%CI=1.052~9.753),and diabetes(OR=2.950,95%CI=1.259~6.914)were risk fac-tors for stroke patients' nerve functional recovery.3-Months after stroke(OR=0.121,95%CI=0.054~0.260),1-year after stroke(OR=0.012,95%CI=0.004~0.028),low tea-consumption(OR=0.146,95%CI=0.067~0.308),and regular tea-con-sumption(OR=0.013,95%CI=0.005~0.031)were protective factors for stroke patients to restore quality of life;age(OR=1.066,95%CI=1.027~1.108),coronary heart disease(OR=2.109,95%CI=1.1159~4.054),and hypertension(OR=2.053,95%CI=1.126~3.773)were risk factors for the recovery of quality of life among stroke patients.Conclusion:Long-term low-dose consumption of partridge tea can reduce the incidence of stroke and improve the clinical symptoms of stroke patients.

严春文;李林美;潘莉;吴淇慧;顾勇

广州中医药大学附属海南中医院手术室,海南 海口 570203广州中医药大学附属海南中医院脑病科,海南 海口 570203广州中医药大学附属海南中医院医院办公室,海南 海口 570203广州中医药大学附属海南中医院临床研究中心,海南 海口 570203

临床医学

鹧鸪茶中风老爸茶临床症状

Partridge teaStrokeLaoba teaClinical symptoms

《海南医学院学报》 2024 (023)

1798-1804 / 7

This study was supported by the Project of Hainan Clinical Medical Research Center(LCYX202209)and Joint Program on Health Science&Technology Innovation of Hainan Province(WSJK2024QN017) 海南省临床医学研究中心项目(LCYX202209);海南省卫生健康科技创新联合项目资助(WSJK2024QN017)

10.13210/j.cnki.jhmu.20240828.001

评论